NASDAQ$MLAB

Mesa Laboratories Inc · Q4 2024 earnings

Q4 2024 earnings · · Investor relations

Briefing

Mesa Labs reported a loss due to a non-cash impairment charge, but revenues increased and non-GAAP adjusted operating income also increased.

Mesa Labs' Q4 2024 results showed a net loss primarily due to a significant non-cash impairment charge. However, revenues increased by 6% compared to Q4 2023, driven by the GKE acquisition. Non-GAAP adjusted operating income excluding unusual items increased by 26.3%.

  • Revenues increased by 6% compared to Q4 2023, driven by the GKE acquisition.
  • Non-GAAP core organic revenues decreased by 3.5%.
  • Operating loss was $(271,284), including a $274,533 non-cash impairment charge.
  • Non-GAAP adjusted operating income excluding unusual items increased by 26.3%.

Headline financials

Total Revenue

$58.9M

Previous: $55.6M+6.0%
EPS (adj)

$2.77

Previous: $1.94+42.8%
Capital Expenditures

$535K

Previous: $1.03M-47.9%
Free Cash Flow

$12.3M

Previous: $11.5M+7.4%
Net Income

-$255M

Previous: $611K-41766.6%
Operating Income

-$271M

Previous: $517K-52572.7%
Gross Profit

$31.1M

Previous: $33.2M-6.4%
Stock-Based Comp

$2.79M

Previous: $2.68M+4.2%

Revenue & EPS history

Mesa Labs · Revenue · Quarterly

$58.9M

Q4 2024+6%vs Q4 2023
Beat estimate in 7 of 15 quarters(47%)
ActualEstimate

Revenue by segment

Mesa Labs · $63.7M total across 4 segments · Q4 2026

  • Sterilization and Disinfection Control
    $29.1M
  • Calibration Solutions
    $13.6M
  • Clinical Genomics
    $12.2M
  • Biopharmaceutical Development
    $8.85M

Forward guidance

Mesa Labs is focused on deepening its presence in the Asia Pacific region and realizing synergies from the GKE acquisition. The company is also prepared to refine its business strategy for Clinical Genomics to adapt to changes in FDA regulations. Mesa will continue to leverage the Mesa Way to stay nimble in FY25.

Tailwinds

  • Deepening presence in the Asia Pacific region.
  • Realizing synergies from the GKE acquisition.
  • Moderating headwinds in capital expenditures within the biopharmaceutical vertical.
  • Expanded sales and marketing by 80 bps as a percentage of revenues.
  • Expanded AOI excluding unusual items percentages.

Headwinds

  • Ongoing macroeconomic uncertainty.
  • Regulatory uncertainty related to FDA regulations of lab developed tests.
  • Need to refine business strategy for Clinical Genomics.
  • Potential implications to Mesa or acquired customers after the effective date of the regulation.
  • Ongoing impact of the economic slowdown in China.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+0.1%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-0.1%

Avg return

30 days after

55%

35 / 64 earnings

Positive

+26.6%

Q2 2023

Best reaction

-24.9%

Q1 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026
Q3 2026+8.7%+15.9%+8.8%
Q2 2026+2.1%+6.7%+3.7%
Q1 2026-24.9%-16.0%-15.9%
Q4 2025-9.3%-13.5%-12.8%
Q3 2025+2.5%+10.3%+3.2%
Q2 2025-11.4%-16.2%-7.6%
Q1 2025+5.8%+11.8%+13.4%
Q4 2024+13.3%+5.5%-3.4%
Q3 2024+2.0%-0.2%+18.9%
Q2 2024+0.1%-8.8%+2.0%
Q1 2024+8.0%+10.3%+11.4%
Q4 2023-2.2%-7.7%-11.7%
Q3 2023-7.4%-8.6%-13.5%
Q2 2023+26.6%+31.2%+39.1%
Q1 2023-5.5%-10.7%-23.5%
Q4 2022-3.7%-2.7%-6.1%
Q3 2022-3.9%-2.0%-5.8%
Q2 2022+4.0%+1.4%-0.1%
Q1 2022+0.4%-1.4%-3.8%
Q4 2021+4.7%+6.4%+9.6%
Q3 2021+0.9%-0.4%-5.2%
Q2 2021-0.4%+2.7%+2.1%
Q1 2021+2.0%-1.5%-1.4%
Q4 2020-5.7%-6.5%-18.6%
Q3 2020-7.2%-2.4%-13.9%
Q2 2020-0.2%-4.7%+3.3%
Q1 2020+6.6%+7.0%-7.3%
Q4 2019-21.1%-19.3%-2.3%
Q3 2019+0.6%+3.4%+2.2%
Q2 2019+0.9%+3.0%+20.4%
Q1 2019-2.7%-0.3%+3.5%
Q4 2018+16.3%+15.4%+31.3%
Q3 2018-5.1%-14.2%-8.0%
Q2 2018-17.2%-19.7%-19.7%
Q1 2018+5.2%+1.6%-2.5%
Q4 2017-6.5%-13.3%-12.3%
Q3 2017+6.4%+1.4%+5.2%
Q2 2017-1.3%-0.8%-1.1%
Q1 2017-4.3%-10.4%-10.5%
Q4 2016+12.7%+26.5%+23.1%
Q3 2016-4.8%
Q2 2016+1.9%
Q1 2016+13.3%
Q4 2015+2.1%
Q3 2015+0.8%
Q2 2015+10.4%
Q1 2015-2.0%
Q4 2014-4.0%
Q3 2013-0.2%
Q3 2014-0.2%
Q2 2014-0.1%
Q1 2014-3.5%
Q4 2013-0.2%
Q2 2013-1.8%
Q1 2013-0.8%
Q4 2012+2.5%
Q3 2011+1.3%
Q3 2012+1.3%
Q2 2011+1.5%
Q2 2012+1.5%
Q4 2011+0.0%
Q1 2011+0.0%
Q1 2012+0.0%
Q4 2010+0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro